Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
Status:
Recruiting
Trial end date:
2021-05-30
Target enrollment:
Participant gender:
Summary
It was difficult to obtain clinical benefits through traditional chemotherapy and
radiotherapy for the patients who have recurrence or metastasis tumor even though they have
received first-line chemotherapy or combined radiotherapy before, but failed.The aim of this
study was to evaluate the safety and efficacy of apatinib, an anti-angiogenesis drug, in the
treatment of patients with advanced esophageal squamous cell carcinoma who had recurrence or
metastasis after radical resection